Addition of Japanese patents, Eddie Pharmaceutical's overseas layout for anti-HIV new drugs accelerates.

Recently, Jiangsu Edi Pharmaceutical Group officially received a patent certificate issued by the Japan Patent Office, adding another card to the global layout of the company's core anti-AIDS drug and new type of integrase inhibitor ACC017. As of now, the Phase III clinical trial of ACC017 has been officially launched, and its compound preparation ADC118 has also been approved for clinical use, with the research and development process steadily advancing.